Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 154

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 154
---
 offering, we expect to incur additional costs associated with operating as a public company. As of December 31, 2024, we had cash and cash equivalents and marketable securities of $28.0 million. Based on our current plans, we believe that our existing cash and cash equivalents and marketable securities, together with the net proceeds from this offering, will be sufficient to meet our anticipated operating and capital expenditure requirements through . We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:

| • |     | the scope, progress, results, and costs of researching and developing                              
 LB-102 for our current and future indications, as well as other product candidates we may develop; |

| • |     | the timing of, and the costs involved in, obtaining marketing approvals for                                    
 LB-102 for our current and future indications, as well as future product candidates we may develop and pursue; |

| • |     | the number of future indications and product candidates that we pursue and their development requirements; |

| • |     | if approved, the costs of commercialization activities for LB-102 for the                                                                                                                                                                              
 treatment of acute schizophrenia, bipolar depression or any other approved indication, or any other product candidate that receives regulatory approval to the extent such costs are not the responsibility of any future collaborators, including the 
 costs and timing of establishing product sales, marketing, distribution, and manufacturing capabilities;                                                                                                                                               |

| • |     | subject to receipt of regulatory approval, revenue, if any, received from commercial sales of LB-102 for any program or revenues received from any future product candidates; |

| • |     | the extent to which we in-license or acquire rights to other products, 
 product candidates, or technologies;                                   |

| • |     | our headcount growth and associated costs as we expand our organization to achieve our objectives; |

| • |     | the costs of preparing, filing, and prosecuting patent applications, and maintaining and protecting our   
 intellectual property rights, including enforcing and defending intellectual property related claims; and |

| • |     | the costs of operating as a public company. |

A change in the outcome of any of these or other variables with respect to